MarketCap
Facebook
X
TelegramQuarterly report 2025-Q2
added 07-31-2025
Bristol-Myers Squibb Company Gross Profit 2011-2026 | BMY
Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.
Calculation formula:Importance for business:
Gross Profit = Revenue – Cost of Goods Sold (COGS)
Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:
- Raw materials and supplies
- Wages of production personnel
- Depreciation of equipment
- Transportation and warehousing costs (if directly related to production)
- Assessing core business profitability
If gross profit is declining, it may indicate rising production costs or falling sales. - Financial planning
Gross profit is the basis for calculating other key metrics, such as operating and net profit. - Benchmarking against competitors
Gross profit analysis helps compare the efficiency of different companies within the same industry. - Insights into pricing effectiveness
If gross profit is low, the company may be pricing too low or failing to control costs effectively.
- Increase in raw material and supply costs
- Rising production expenses
- Price reductions due to competition
- Decrease in sales volume
- Currency exchange rate fluctuations (for imports/exports)
Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.
Annual Gross Profit Bristol-Myers Squibb Company
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | 18.1 B | 16 B | 14.7 B | 14.5 B | 12.7 B | 11.9 B | 11.8 B | 13 B | 15.6 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 18.1 B | 11.8 B | 14.3 B |
Quarterly Gross Profit Bristol-Myers Squibb Company
| 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 8.16 B | 8.04 B | 7.43 B | 7.12 B | 5.45 B | 4.22 B | 4.3 B | 4.1 B | 4.3 B | 4.06 B | 4.1 B | 3.63 B | 3.77 B | 3.68 B | 3.58 B | 3.66 B | 3.86 B | 3.62 B | 3.66 B | 3.34 B | 3.34 B | 2.97 B | 3.15 B | 3.19 B | 3.29 B | 2.91 B | 2.9 B | 2.84 B | 3.17 B | 2.89 B | 2.94 B | 2.77 B | 3.12 B | 2.75 B | 3.2 B | 3.95 B | 4.09 B | 3.94 B | 3.95 B | 3.67 B |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 8.16 B | 2.75 B | 3.98 B |
Gross Profit of other stocks in the Biotechnology industry
| Issuer | Gross Profit | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
180 M | - | 2.43 % | $ 254 M |  Germany |
 |
Aclaris Therapeutics
ACRS
|
172 K | $ 3.01 | 3.79 % | $ 233 M |  USA |
 |
AIkido Pharma
AIKI
|
10 K | - | 1.93 % | $ 17.4 M | USA |
 |
Alterity Therapeutics Limited
ATHE
|
177 K | $ 3.08 | 0.65 % | $ 7.41 B |  Australia |
 |
Ampio Pharmaceuticals
AMPE
|
-523 K | - | -11.43 % | $ 502 K | USA |
 |
Midatech Pharma plc
MTP
|
-428 K | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.52 B | - | - | $ 40.3 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
12.1 | - | -1.52 % | $ 24.7 M | USA |
 |
Ascendis Pharma A/S
ASND
|
319 M | $ 213.24 | 1.87 % | $ 5 B |  Danmark |
 |
BioDelivery Sciences International
BDSI
|
14 M | - | -4.8 % | $ 255 M | USA |
 |
Athersys
ATHX
|
1.44 M | - | 3.77 % | $ 22.4 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
774 M | - | - | - |  Russia |
 |
Acasti Pharma
ACST
|
-32.3 K | - | 4.01 % | $ 150 M |  Canada |
 |
Bellicum Pharmaceuticals
BLCM
|
500 | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
53.8 M | - | -7.31 % | $ 87 M | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
1.12 M | - | -15.15 % | $ 60.3 M | Britain |
 |
bluebird bio
BLUE
|
-4.03 M | - | - | $ 546 M | USA |
 |
Albireo Pharma
ALBO
|
39.2 M | - | -0.23 % | $ 916 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
2.03 M | $ 0.2 | 8.46 % | $ 435 M |  Israel |
 |
Amphastar Pharmaceuticals
AMPH
|
374 M | $ 26.78 | -0.81 % | $ 1.3 B | USA |
 |
BeiGene, Ltd.
BGNE
|
3.22 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Anika Therapeutics
ANIK
|
103 M | $ 9.61 | 0.63 % | $ 141 M | USA |
 |
Catalyst Biosciences
CBIO
|
109 M | $ 11.86 | 2.24 % | $ 781 M | USA |
 |
Certara
CERT
|
129 M | $ 8.81 | -0.56 % | $ 1.41 B | USA |
 |
Celldex Therapeutics
CLDX
|
5.48 M | $ 27.16 | 2.76 % | $ 1.75 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
319 K | - | -6.81 % | $ 3.04 B | USA |
 |
Acer Therapeutics
ACER
|
1.27 M | - | 2.71 % | $ 14 M | USA |
 |
Cellectis S.A.
CLLS
|
37.7 M | $ 4.84 | 1.26 % | $ 116 M |  France |
 |
Axon Enterprise
AXON
|
1.24 B | $ 567.93 | -0.73 % | $ 43 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
90 K | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
45.8 M | $ 2.6 | 1.96 % | $ 16.3 M | USA |
 |
AstraZeneca PLC
AZN
|
43.9 B | $ 91.93 | -0.63 % | $ 96.9 B | Britain |
 |
Acorda Therapeutics
ACOR
|
119 M | - | -24.86 % | $ 820 K | USA |
 |
Brickell Biotech
BBI
|
1.82 K | - | -5.38 % | $ 6.06 M | USA |
 |
ChromaDex Corporation
CDXC
|
61.6 M | - | -0.88 % | $ 598 M | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
371 M | $ 11.29 | -3.01 % | $ 730 M | USA |